MoonLake Immunotherapeutics (MLTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MoonLake Immunotherapeutics stock (MLTX) is currently trading at $18.02. Analyst consensus price target for MLTX is $25.86. WallStSmart rates MLTX as Sell.
- MLTX PE ratio analysis and historical PE chart
- MLTX PS ratio (Price-to-Sales) history and trend
- MLTX intrinsic value — DCF, Graham Number, EPV models
- MLTX stock price prediction 2025 2026 2027 2028 2029 2030
- MLTX fair value vs current price
- MLTX insider transactions and insider buying
- Is MLTX undervalued or overvalued?
- MoonLake Immunotherapeutics financial analysis — revenue, earnings, cash flow
- MLTX Piotroski F-Score and Altman Z-Score
- MLTX analyst price target and Smart Rating
MoonLake Immunotherapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
MoonLake Immunotherapeutics (MLTX) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
MoonLake Immunotherapeutics (MLTX) Key Strengths (1)
80.68% of shares held by major funds and institutions
Supporting Valuation Data
MoonLake Immunotherapeutics (MLTX) Areas to Watch (3)
Company is destroying shareholder value
Premium pricing at 3.8x book value
Small-cap company with higher risk but more growth potential
MoonLake Immunotherapeutics (MLTX) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Book, Market Cap. Some valuation metrics including Price/Book (3.83) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -60.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MLTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for MoonLake Immunotherapeutics (MLTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
MoonLake Immunotherapeutics operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -59M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact MoonLake Immunotherapeutics.
Bottom Line
MoonLake Immunotherapeutics offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About MoonLake Immunotherapeutics(MLTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on developing innovative therapies for chronic inflammatory diseases using its proprietary drug delivery platform. The firm is currently advancing its lead product candidate, a novel interleukin-17 inhibitor, through clinical trials, aiming to provide transformative treatment solutions that could significantly enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake is well-positioned to impact the immunotherapy market, addressing critical unmet medical needs while creating substantial value for shareholders.